Ends Q1 with $603 M Cash, Enrolls 5,500 in Phase 3 VK2735 Trials
Viking Therapeutics ended Q1 2026 with $603 million cash and fully enrolled over 5,500 patients in its subcutaneous VK2735 Phase 3 VANQUISH-1 and -2 obesity trials. It expects to initiate the Phase 3 oral VK2735 trial in 4Q26, report maintenance dosing data in 3Q26 and start VK3019 Phase 1 in 2Q26.
1. Q1 Financial Highlights
Viking closed the first quarter of 2026 with a strong cash balance of $603 million, providing ample runway for continued clinical development and operational activities. The robust cash position underscores fiscal discipline and supports upcoming trial milestones without immediate financing needs.
2. Phase 3 Subcutaneous VK2735 Trials
Both VANQUISH-1 and VANQUISH-2 trials, evaluating weekly subcutaneous VK2735 in adults with obesity (with and without type 2 diabetes), are fully enrolled with more than 5,500 patients randomized across multiple dose arms and placebo. Each study will assess percent body weight change at 78 weeks, with extension phases allowing participants to continue treatment.
3. Pipeline Updates and Upcoming Milestones
The company anticipates initiating its oral VK2735 Phase 3 trial in the fourth quarter of 2026, potentially delivering the first oral dual GLP-1/GIP agonist for obesity. Maintenance dosing data for subcutaneous VK2735 are expected in third-quarter 2026, and a Phase 1 trial for the amylin agonist VK3019 is slated to begin in second-quarter 2026.